•  

Posts Tagged: orphan indications

Triphase secures FDA orphan drug designation for Marizomib in Malignant Glioma

TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma. Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ... Read more

Funding call: MaRS Innovation Industry Access Program (MI-IAP) accepting applications to February 6

Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck. The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs. The program is open to any researcher affiliated with MI's 16 member ... Read more

MaRS Innovation Industry Access Program (MI-IAP) accepting applications until April 10

Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck. The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs. First run in November 2013, the MI-IAP allows researchers to easily ... Read more